Clinical Trial

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-25
Trial Details
NCT Number NCT07589608
Lead Sponsor Eli Lilly and Company
Conditions Overweight, Obesity
Enrollment 400 participants
Start Date 2026-05-15
Primary Completion 2027-09 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-06